Ignite Creation Date:
2024-05-06 @ 4:13 PM
Last Modification Date:
2024-10-26 @ 2:06 PM
Study NCT ID:
NCT04914546
Status:
COMPLETED
Last Update Posted:
2022-11-21
First Post:
2021-06-01
Brief Title:
A Study of LY3819469 in Healthy Participants
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A Single-Ascending Dose Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of LY3819469
Status:
COMPLETED
Status Verified Date:
2022-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a 2-part study In Part A the main purpose is to evaluate the safety and tolerability of the study drug LY3819469 in healthy participants with high lipoprotein a Lpa levels How the body processes the study drug and the effect of the study drug on blood Lpa levels will also be investigated Part B will mainly evaluate the safety and tolerability of LY3819469 as well as how the body processes the study drug in Japanese participants The study may last up to 53 and 29 weeks for each participant in Parts A and B respectively
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| J3L-MC-EZEA | OTHER | Eli Lilly and Company | None |